Pulmonary late‐phase allergic reactions

Blythe, Stephen A.; Lemanske, Robert F.

doi:10.1002/ppul.1950040310

Cited by 9 publications

(5 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The LPR in humans is thought to be linked to the increased responsiveness to bronchoconstricting agents that is characteristic of asthma [32, 33]. The present study has shown a distinct dissociation between AHR and the physiological response to allergen inhalation in this model of asthma.…”

Section: Discussionsupporting

confidence: 50%

Ovalbumin‐sensitized mice are good models for airway hyperresponsiveness but not acute physiological responses to allergen inhalation

Zosky

Larcombe

White

et al. 2007

Clin Experimental Allergy

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 50%

Ovalbumin‐sensitized mice are good models for airway hyperresponsiveness but not acute physiological responses to allergen inhalation

Zosky

Larcombe

White

et al. 2007

Clin Experimental Allergy

View full text Add to dashboard Cite

show abstract

“…Of note, is the fact that it has been demonstrated that only those sheep that develop a LPR have AHR 24 h after challenge [99] (Fig. 2), which again, is similar to asthmatics [79, 80]. In terms of drug efficacy, there are also striking similarities between this model and asthma with cromolyn and corticosteroids being effective therapies for allergic airway responses in the sheep [100].…”

Section: Relative Merits Of Different Speciesmentioning

confidence: 75%

“…The acute response in BN rats is characterized by both an EPR and an LPR that peaks approximately 6–8 h after challenge [77]. In humans, there is an established link between acute responses to allergen inhalation, in particular the LPR, and the development of non‐specific AHR [79, 80]. Consequently, the ability to generate an EPR, LPR and AHR in rats (Fig.…”

Section: Relative Merits Of Different Speciesmentioning

confidence: 99%

Animal models of asthma

Zosky

Sly

2007

Clin Experimental Allergy

260

195

View full text Add to dashboard Cite

SummaryAnimal models of asthma are a tool that allows studies to be conducted in the setting of an intact immune and respiratory system. These models have highlighted the importance of T-helper type 2 driven allergic responses in the progression of asthma and have been useful in the identification of potential drug targets for interventions involving allergic pathways. However, a number of drugs that have been shown to have some efficacy in animal models of asthma have shown little clinical benefit in human asthmatics. This may be due to a number of factors including the species of animal chosen and the methods used to induce an asthmatic phenotype in animals that do not normally develop a disease that could be characterized as asthma. The range of animal models available is vast, with the most popular models being rodents (inbred mice and rats) and guinea-pigs, which have the benefit of being easy to handle and being relatively cost effective compared with other models that are available. The recent advances in transgenic technology and the development of species-specific probes, particularly in mice, have allowed detailed mechanistic studies to be conducted. Despite these advances in technology, there are a number of issues with current animal models of asthma that must be recognized including the disparity in immunology and anatomy between these species and humans, the requirement for adjuvant during senitization in most models, the acute nature of the allergic response that is induced and the use of adult animals as the primary disease model. Some larger animal models using sheep and dogs have been developed that may address some of these issues but they also have different biology from humans in many ways and are extremely costly, with very few probes available for characterizing allergic responses in the airway in these species. As research in this area continues to expand, the relative merits and limitations of each model must be defined and understood in order to evaluate the information that is obtained from these models and to extrapolate these findings to humans so that effective drug therapies can be developed. Despite these issues, animal models have been, and will continue to be, vital in understanding the mechanisms that are involved in the development and progression of asthma.

show abstract

“…Of note, is the fact that it has been demonstrated that only those sheep that develop a LPR have AHR 24 h after challenge [99] (Fig. 2), which again, is similar to asthmatics [79,80]. In terms of drug efficacy, there are also striking similarities between this model and asthma with cromolyn and corticosteroids being effective therapies for allergic airway responses in the sheep [100].…”

Section: Sheepmentioning

confidence: 61%

“…The acute response in BN rats is characterized by both an EPR and an LPR that peaks approximately 6-8 h after challenge [77]. In humans, there is an established link between acute responses to allergen inhalation, in particular the LPR, and the development of non-specific AHR [79,80]. Consequently, the ability to generate an EPR, LPR and AHR in rats (Fig.…”

Section: Ratsmentioning

confidence: 99%

Animal models of asthma

Akkoç¹

2010

mpj

View full text Add to dashboard Cite

Animal models of asthma are a tool that allows studies to be conducted in the setting of an intact immune and respiratory system. These models have highlighted the importance of T-helper type 2 driven allergic responses in the progression of asthma and have been useful in the identification of potential drug targets for interventions involving allergic pathways. However, a number of drugs that have been shown to have some efficacy in animal models of asthma have shown little clinical benefit in human asthmatics. This may be due to a number of factors including the species of animal chosen and the methods used to induce an asthmatic phenotype in animals that do not normally develop a disease that could be characterized as asthma. The range of animal models available is vast, with the most popular models being rodents (inbred mice and rats) and guinea-pigs, which have the benefit of being easy to handle and being relatively cost effective compared with other models that are available. The recent advances in transgenic technology and the development of species-specific probes, particularly in mice, have allowed detailed mechanistic studies to be conducted. Despite these advances in technology, there are a number of issues with current animal models of asthma that must be recognized including the disparity in immunology and anatomy between these species and humans, the requirement for adjuvant during senitization in most models, the acute nature of the allergic response that is induced and the use of adult animals as the primary disease model. Some larger animal models using sheep and dogs have been developed that may address some of these issues but they also have different biology from humans in many ways and are extremely costly, with very few probes available for characterizing allergic responses in the airway in these species. As research in this area continues to expand, the relative merits and limitations of each model must be defined and understood in order to evaluate the information that is obtained from these models and to extrapolate these findings to humans so that effective drug therapies can be developed. Despite these issues, animal models have been, and will continue to be, vital in understanding the mechanisms that are involved in the development and progression of asthma.

show abstract

Pulmonary late‐phase allergic reactions

Cited by 9 publications

References 62 publications

Ovalbumin‐sensitized mice are good models for airway hyperresponsiveness but not acute physiological responses to allergen inhalation

Ovalbumin‐sensitized mice are good models for airway hyperresponsiveness but not acute physiological responses to allergen inhalation

Animal models of asthma

Animal models of asthma

Contact Info

Product

Resources

About